Latest News
INVESTIGATION ALERT: Grifols SA Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
NEW YORK, NY - (NewMediaWire) - August 31, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Grifols SA is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
NEW YORK, NY - (NewMediaWire) - August 29, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Grifols SA Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
NEW YORK, NY - (NewMediaWire) - August 27, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
GRFS Is Being Investigated for Potential Securities Law Violations Contact Kaplan Fox & Kilsheimer LLP
NEW YORK, NY - (NewMediaWire) - August 02, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Kaplan Fox & Kilsheimer LLP is Investigating Possible Securities Law Violations against Grifols SA (GRFS)
NEW YORK, NY - (NewMediaWire) - July 31, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Kaplan Fox & Kilsheimer LLP is Investigating Grifols SA (GRFS) for Potential Securities Law Violations
NEW YORK, NY - (NewMediaWire) - July 30, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Grifols, S.A. (NASDAQ: GRFS) Short Seller Report: Kaplan Fox Investigates Grifols, S.A.
NEW YORK, NY - (NewMediaWire) - April 2, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (NASDAQ: GRFS) securities. Click Here to Join the Investigation.
Grifols, S.A. (NASDAQ: GRFS) Shareholder Alert: Kaplan Fox Investigates Claims on Behalf of Grifols, S.A. Investors
NEW YORK, NY - (NewMediaWire) - March 28, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (Nasdaq: GRFS) securities. Click Here to Join the Investigation.
Grifols, S.A. (NASDAQ: GRFS) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Grifols, S.A. for Potential Securities Violations
NEW YORK, NY - (NewMediaWire) - March 27, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (Nasdaq: GRFS) securities. Click Here to Join the Investigation.
Kaplan Fox & Kilsheimer LLP Investigates Grifols, S.A. (Nasdaq: GRFS)
NEW YORK, NY - (NewMediaWire) - March 22, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Grifols, S.A. (Nasdaq: GRFS) securities. Click Here to Join the Investigation.
A humorous look at the companies that caught our eye, for better or worse, this week
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
/PRNewswire/ -- DelveInsight's 'Dry Eye Disease Pipeline Insight – 2023' report provides comprehensive global coverage of pipeline dry eye disease therapies in...
Why Shares of Grifols Were Up Tuesday
The company gave first-quarter numbers.
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023
/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
/PRNewswire/ -- Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research,...
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is...
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving...
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving...
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond
These three healthcare stocks should hold their value for years.
Illumina Ventures Announces Promotion and Additions to its Investment Team
Illumina Ventures , today announced the promotion of Malek Faham, MD, PhD, to Chief Scientist having previously served as both a Venture Partner and Entrepreneur in Residence (EIR). In addition, Charles Lin, PhD, has joined the team as a...
Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines
/PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track...
GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc. , a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of ...
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19
First-in-human study evaluating recombinant hyperimmunes
Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer
SAN CARLOS, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today...
GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564
--Reduced checkpoint inhibitor activity of GIGA-564 versus current anti-CTLA-4 inhibitors results in superior anti-tumor activity and lower toxicity in murine models -- --Data supports advancement of GIGA-564 into the clinic for cancer...